<p>加利福尼亞州聖地亞哥 / ACCESS Newswire /2025 年 12 月 4 日/ Dermata Therapeutics, Inc.（&#34;Dermata&#34;或&#34;公司&#34;），一家以科學為驅動的皮膚科解決方案領導者，今天宣佈將很快揭曉其非處方（&#34;OTC&#34;）護膚業務的新品牌名稱，代表其向更直接、以科學為首的皮膚科創新時代的演變。雖然該名稱在正式揭曉之前仍然保密，但公司提供了一個關於推動這一新身份的使命和本質的初步瞭解——這一身份專為期望從產品、科學和背後的公司中獲得更多的護膚消費者社區而創建。</p>
<p>致力於開創一個強大而非懲罰性的護膚新領域。</p>
<p>Dermata 的使命是通過將祖傳智慧與科學創新相結合，重新定義皮膚科的可能性，從而創造出一種全新的類別方法。Dermata 希望賦予人們體驗一種全新效能的能力，而這種效能絕不會以健康和福祉為代價。</p>
<p>他們的使命為新品牌名稱及其伴隨的視覺和語言表達奠定了基礎。Dermata 的療法、技術和產品體驗將通過一種誠實、自信且毫不妥協地根植於可量化表現的視角來框架。</p>
<p><strong>為好奇者而建。</strong></p>
<p>當今的精明護膚消費者不再滿足於被動的護膚程序或模糊的承諾。他們將臨牀嚴謹與體驗直覺相結合；他們對機制的理解與對質地的欣賞同樣深刻；他們尋求既經典又前沿的解決方案，以釋放新的可能性。Dermata 計劃針對這些對所用產品有深入研究好奇心的消費者。他們是成熟的採用者，想要了解產品的工作原理、成分以及效果。</p>
<p>Dermata 的新品牌身份是以這些好奇的個體為中心塑造的。它呼應了一代人，他們提出更好的問題，要求更好的答案，並期待更好的科學，這與 Dermata 的建立方式相似。</p>
<p><strong>提供指數級成果的產品。</strong></p>
<p>Dermata 旨在開發一系列對有效護膚程序至關重要的產品。他們相信，在一個充滿過於複雜且效果不佳的治療方案的世界中，結合他們的_Spongilla_技術將挑戰並重塑消費者的護膚方式。公司計劃通過創造高效、有效的產品，使護膚程序的每個部分都能更好地發揮作用。</p>
<p>Dermata 希望消費者在使用其產品時能感受到護膚程序的提升。</p>
<p><strong>一個體現這一雄心的名稱。</strong></p>
<p>雖然 Dermata 在正式揭曉之前仍然保密品牌名稱，但公司暗示該名稱捕捉了：</p>
<ul>
<li>經得起時間考驗的療法</li>
<li>持續的創新</li>
<li>相信真正的肌膚轉變始於有目的的科學</li>
</ul>
<p>這一揭曉預計將標誌着一個新篇章的開始——一個由更強的消費者對齊、更清晰的產品差異化和圍繞創新的更明確敍述所定義的篇章。</p>
<p><strong>展望未來。</strong></p>
<p>Dermata 將在接下來的幾周內揭曉新品牌名稱和身份。包括視覺資產、產品定位和發佈階段溝通在內的更多信息將在未來幾個月內分享。公司計劃在 2026 年中期推出其首個 OTC 每週一次的痤瘡套件。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿中不嚴格屬於歷史性質的聲明為前瞻性聲明。這些聲明基於公司的當前信念和預期，並且可能會不時出現新的風險。前瞻性聲明受到已知和未知的風險、不確定性、假設和其他因素的影響，包括但不限於與以下內容相關的聲明：Dermata 轉變為優先考慮 OTC 皮膚科產品；任何未來公告的時間；Dermata 戰略轉變的預期好處，包括加速其商業化路徑、減少監管負擔以及擴展到更廣泛的消費市場；任何計劃或未來 OTC 產品發佈的預期時間和成功；消費者對 Dermata 任何產品候選的接受程度；以及公司在證券交易委員會的備案中描述的其他因素。這些前瞻性聲明通常通過使用&#34;可能&#34;、&#34;可以&#34;、&#34;應該&#34;、&#34;會&#34;、&#34;相信&#34;、&#34;預期&#34;、&#34;預測&#34;、&#34;估計&#34;、&#34;期待&#34;、&#34;打算&#34;、&#34;計劃&#34;、&#34;繼續&#34;、&#34;展望&#34;、&#34;將&#34;、&#34;潛在&#34;及類似的未來或前瞻性性質的聲明來識別。這些聲明僅是基於當前信息和預期的預測，並涉及許多風險和不確定性。實際事件或結果可能因各種因素而與任何此類聲明中預測的結果有重大差異，包括藥物開發、批准和商業化固有的風險和不確定性，以及臨牀試驗的過去結果可能不代表未來試驗結果的事實。有關這些和其他因素的討論，請參閲 Dermata 在證券交易委員會的備案。您被警告不要對這些前瞻性聲明過度依賴，這些聲明僅在本日期時有效。此警告是根據 1995 年《私人證券訴訟改革法》的安全港條款作出的。所有前瞻性聲明均完全受到此警告聲明的限制，Dermata 沒有義務修訂或更新本新聞稿，以反映本日期後的事件或情況，除非法律要求。</p>
<p><strong>Dermata 投資者：</strong></p>
<p>Cliff Mastricola</p>
<p>投資者關係</p>
<p>cmastricola@dermatarx.com</p>
<p><strong>來源：</strong> Dermata Therapeutics</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>

DRMA

<p>Dermata Therapeutics, Inc. 宣佈計劃為其 OTC 護膚系列推出全新的品牌形象，強調以科學驅動的皮膚病學創新。該品牌旨在通過結合傳統智慧與科學創新來重新定義護膚，目標是滿足那些對科學和效果有更高要求的消費者。新的品牌形象將很快揭曉，首個 OTC 痘痘護理套件預計在 2026 年中旬推出。前瞻性聲明提醒有關產品開發和商業化中的風險和不確定性</p>

<p>SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc.  (&#34;Dermata&#34; or the &#34;Company&#34;), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name for its over-the-counter (&#34;OTC&#34;) skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of <em>skincare consumers</em> who expect more from their products, their science, and the companies behind them.</p>
<div class="lb-trans"><p>加利福尼亞州聖地亞哥 / ACCESS Newswire /2025 年 12 月 4 日/ Dermata Therapeutics, Inc.（&#34;Dermata&#34;或&#34;公司&#34;），一家以科學為驅動的皮膚科解決方案領導者，今天宣佈將很快揭曉其非處方（&#34;OTC&#34;）護膚業務的新品牌名稱，代表其向更直接、以科學為首的皮膚科創新時代的演變。雖然該名稱在正式揭曉之前仍然保密，但公司提供了一個關於推動這一新身份的使命和本質的初步瞭解——這一身份專為期望從產品、科學和背後的公司中獲得更多的護膚消費者社區而創建。</p>
</div><p>On a mission to forge a new realm of skincare that is powerful, not punishing.</p>
<div class="lb-trans"><p>致力於開創一個強大而非懲罰性的護膚新領域。</p>
</div><p>Dermata's mission is to redefine what's possible in dermatology by melding ancestral wisdom with scientific innovation to create an entirely new approach to the category. Dermata wants to empower people to experience a new form of potency that never comes at the expense of health and wellbeing.</p>
<div class="lb-trans"><p>Dermata 的使命是通過將祖傳智慧與科學創新相結合，重新定義皮膚科的可能性，從而創造出一種全新的類別方法。Dermata 希望賦予人們體驗一種全新效能的能力，而這種效能絕不會以健康和福祉為代價。</p>
</div><p>Their mission serves as the foundation for the new brand name and its accompanying visual and verbal expression. Dermata's therapies, technologies, and product experiences will be framed through a lens that is honest, confident, and uncompromisingly rooted in quantifiable performance.</p>
<div class="lb-trans"><p>他們的使命為新品牌名稱及其伴隨的視覺和語言表達奠定了基礎。Dermata 的療法、技術和產品體驗將通過一種誠實、自信且毫不妥協地根植於可量化表現的視角來框架。</p>
</div><p><strong>Built for the curious.</strong></p>
<div class="lb-trans"><p><strong>為好奇者而建。</strong></p>
</div><p>Today's sophisticated skincare consumer is no longer content with passive routines or vague promises. They blend clinical rigor with experiential intuition; they understand mechanisms as deeply as they appreciate textures; they seek solutions that are timeless and cutting edge to unleash a new realm of possibilities. Dermata plans to target these consumers who have a deep curiosity to research the products they are putting on their skin. They are mature adopters who want to know how the product works, what are the ingredients, and what are the results.</p>
<div class="lb-trans"><p>當今的精明護膚消費者不再滿足於被動的護膚程序或模糊的承諾。他們將臨牀嚴謹與體驗直覺相結合；他們對機制的理解與對質地的欣賞同樣深刻；他們尋求既經典又前沿的解決方案，以釋放新的可能性。Dermata 計劃針對這些對所用產品有深入研究好奇心的消費者。他們是成熟的採用者，想要了解產品的工作原理、成分以及效果。</p>
</div><p>Dermata's new brand identity was shaped with these curious individuals in mind. It speaks to a generation that asks better questions, demands better answers, and expects better science, similar to how Dermata was built.</p>
<div class="lb-trans"><p>Dermata 的新品牌身份是以這些好奇的個體為中心塑造的。它呼應了一代人，他們提出更好的問題，要求更好的答案，並期待更好的科學，這與 Dermata 的建立方式相似。</p>
</div><p><strong>With products that deliver exponential results.</strong></p>
<div class="lb-trans"><p><strong>提供指數級成果的產品。</strong></p>
</div><p>Dermata aims to develop a line of products that are essential for an effective skincare routine. They believe that in a world filled with treatments that overcomplicate and underdeliver, incorporating their <em>Spongilla</em> technology will challenge and reshape how consumers care for their skin. The Company plans to accomplish this by creating products that are efficient, effective, and make every other part of a skincare routine work better.</p>
<div class="lb-trans"><p>Dermata 旨在開發一系列對有效護膚程序至關重要的產品。他們相信，在一個充滿過於複雜且效果不佳的治療方案的世界中，結合他們的_Spongilla_技術將挑戰並重塑消費者的護膚方式。公司計劃通過創造高效、有效的產品，使護膚程序的每個部分都能更好地發揮作用。</p>
</div><p>Dermata wants consumers to feel the difference when using their products that amplify their skincare routine.</p>
<div class="lb-trans"><p>Dermata 希望消費者在使用其產品時能感受到護膚程序的提升。</p>
</div><p><strong>A name that embodies this ambition.</strong></p>
<div class="lb-trans"><p><strong>一個體現這一雄心的名稱。</strong></p>
</div><p>While Dermata is keeping the brand name confidential ahead of its official reveal, the Company hints that the name captures:</p>
<div class="lb-trans"><p>雖然 Dermata 在正式揭曉之前仍然保密品牌名稱，但公司暗示該名稱捕捉了：</p>
</div><ul>
<li>Time-tested remedies</li>
<li>Perpetual innovation</li>
<li>Belief that true skin transformation begins with purposeful science</li>
</ul>
<div class="lb-trans"><ul>
<li>經得起時間考驗的療法</li>
<li>持續的創新</li>
<li>相信真正的肌膚轉變始於有目的的科學</li>
</ul>
</div><p>The reveal is expected to signal the beginning of a new chapter-one defined by stronger consumer alignment, clearer product differentiation, and a sharpened narrative around innovation.</p>
<div class="lb-trans"><p>這一揭曉預計將標誌着一個新篇章的開始——一個由更強的消費者對齊、更清晰的產品差異化和圍繞創新的更明確敍述所定義的篇章。</p>
</div><p><strong>Looking ahead.</strong></p>
<div class="lb-trans"><p><strong>展望未來。</strong></p>
</div><p>Dermata will unveil the new brand name and identity in the coming weeks. Additional information, including visual assets, product positioning, and launch-phase communications, will be shared over the coming months. The Company plans to launch its first OTC once-weekly acne kit in the middle of 2026.</p>
<div class="lb-trans"><p>Dermata 將在接下來的幾周內揭曉新品牌名稱和身份。包括視覺資產、產品定位和發佈階段溝通在內的更多信息將在未來幾個月內分享。公司計劃在 2026 年中期推出其首個 OTC 每週一次的痤瘡套件。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize OTC dermatology products; the timing of any future announcement; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned or future OTC product launches; consumer acceptance of any of Dermata's product candidates; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;would,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;forecast,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;continue,&#34; &#34;outlook,&#34; &#34;will,&#34; &#34;potential&#34; and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.</p>
<div class="lb-trans"><p>本新聞稿中不嚴格屬於歷史性質的聲明為前瞻性聲明。這些聲明基於公司的當前信念和預期，並且可能會不時出現新的風險。前瞻性聲明受到已知和未知的風險、不確定性、假設和其他因素的影響，包括但不限於與以下內容相關的聲明：Dermata 轉變為優先考慮 OTC 皮膚科產品；任何未來公告的時間；Dermata 戰略轉變的預期好處，包括加速其商業化路徑、減少監管負擔以及擴展到更廣泛的消費市場；任何計劃或未來 OTC 產品發佈的預期時間和成功；消費者對 Dermata 任何產品候選的接受程度；以及公司在證券交易委員會的備案中描述的其他因素。這些前瞻性聲明通常通過使用&#34;可能&#34;、&#34;可以&#34;、&#34;應該&#34;、&#34;會&#34;、&#34;相信&#34;、&#34;預期&#34;、&#34;預測&#34;、&#34;估計&#34;、&#34;期待&#34;、&#34;打算&#34;、&#34;計劃&#34;、&#34;繼續&#34;、&#34;展望&#34;、&#34;將&#34;、&#34;潛在&#34;及類似的未來或前瞻性性質的聲明來識別。這些聲明僅是基於當前信息和預期的預測，並涉及許多風險和不確定性。實際事件或結果可能因各種因素而與任何此類聲明中預測的結果有重大差異，包括藥物開發、批准和商業化固有的風險和不確定性，以及臨牀試驗的過去結果可能不代表未來試驗結果的事實。有關這些和其他因素的討論，請參閲 Dermata 在證券交易委員會的備案。您被警告不要對這些前瞻性聲明過度依賴，這些聲明僅在本日期時有效。此警告是根據 1995 年《私人證券訴訟改革法》的安全港條款作出的。所有前瞻性聲明均完全受到此警告聲明的限制，Dermata 沒有義務修訂或更新本新聞稿，以反映本日期後的事件或情況，除非法律要求。</p>
</div><p><strong>Dermata Investors:</strong></p>
<div class="lb-trans"><p><strong>Dermata 投資者：</strong></p>
</div><p>Cliff Mastricola</p>
<div class="lb-trans"><p>Cliff Mastricola</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>cmastricola@dermatarx.com</p>
<div class="lb-trans"><p>cmastricola@dermatarx.com</p>
</div><p><strong>SOURCE:</strong> Dermata Therapeutics</p>
<div class="lb-trans"><p><strong>來源：</strong> Dermata Therapeutics</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div>

護膚品的新領域即將到來：Dermata 預告新的非處方藥品牌形象